Fig 1: The sensitivity of serum HE4 autoantibody was 67.21%, the specificity was 96.23%. ROC curve analysis showed an AUC of 0.848 (95% CI: 0.776–0.920) for HE4 autoantibody for LC. ROC, receiver operating characteristic; AUC, area under the curve; LC, lung cancer.
Fig 2: Serum levels of autoantibody to HE4 in different subgroups of LC patients. (A) The serum levels of autoantibody to HE4 were significantly higher in patients at III–IV stage than I–II stage (P=0.022). (B) The serum levels of autoantibody to HE4 were not significantly changed in patients with PS 0–1 and 2–4 (P=0.390). (C) The serum levels of autoantibody to HE4 were not significantly changed in patients with WL =5% and WL >5% (P=0.261). WL, weight loss.
Fig 3: Serum levels of autoantibody to HE4 in different groups. (A) The serum levels of autoantibody to HE4 were significantly higher in patients with LC than control subjects (P<0.001). (B) The serum levels of autoantibody to HE4 were significantly higher in BLD patients than healthy donors (P=0.021). (C) The serum levels of autoantibody to HE4 were significantly higher in ADC patients than SCC patients (P=0.006). LC, lung cancer; BLD, benign lung disease; ADC, adenocarcinoma; SCC, squamous cell carcinoma.
Supplier Page from Sino Biological, Inc. for Human WAP5 / WFDC2 / HE4 Protein (His Tag)